

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number
WO 2005/009976 A1

- (51) International Patent Classification⁷: **C07D 237/20**, A61K 31/501, A61P 3/04
- (21) International Application Number:
PCT/DK2004/000483
- (22) International Filing Date: 6 July 2004 (06.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PA 2003 01107 29 July 2003 (29.07.2003) DK
60/492,693 5 August 2003 (05.08.2003) US
- (71) Applicant (for all designated States except US): **NOVO NORDISK A/S** [DK/DK]; Novo Allé, DK-DK Bagsværd (DK).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HOHLWEG, Rolf** [DE/DK]; Nederste Torpenvej 29, DK-3050 Humlebæk (DK).
- (74) Common Representative: **NOVO NORDISK A/S**; Corporate Patents, Novo Allé, DK-DK Bagsværd (DK).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS



(57) Abstract: The present invention relates to piperazines of formula I. The compounds show a high and selective binding affinity for the histamine H₃ receptor, indicating histamine H₃ receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases or

disorders related to the histamine H₃ receptor.



WO 2005/009976 A1

PYRIDAZINYL-PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS

FIELD OF THE INVENTION

The present invention relates to novel piperazines, to the use of these compounds in pharmaceutical compositions, to pharmaceutical compositions comprising the compounds, and to methods of treatment employing these compounds or compositions. The present compounds show a high and selective binding affinity for the histamine H3 receptor, indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases or disorders related to the histamine H3 receptor.

BACKGROUND OF THE INVENTION

The existence of the histamine H3 receptor has been known for several years and the receptor is of current interest for the development of new medicaments. Recently, the human histamine H3 receptor has been cloned. The histamine H3 receptor is a presynaptic autoreceptor located both in the central and the peripheral nervous system, the skin and in organs such as the lung, the intestine, probably the spleen and the gastrointestinal tract. Recent evidence suggests that the H3 receptor shows intrinsic, constitutive activity, *in vitro* as well as *in vivo* (ie it is active in the absence of an agonist). Compounds acting as inverse agonists can inhibit this activity. The histamine H3 receptor has been demonstrated to regulate the release of histamine and also of other neurotransmitters such as serotonin and acetylcholine. A histamine H3 receptor antagonist or inverse agonist would therefore be expected to increase the release of these neurotransmitters in the brain. A histamine H3 receptor agonist, on the contrary, leads to an inhibition of the biosynthesis of histamine and an inhibition of the release of histamine and also of other neurotransmitters such as serotonin and acetylcholine. These findings suggest that histamine H3 receptor agonists, inverse agonists and antagonists could be important mediators of neuronal activity. Accordingly, the histamine H3 receptor is an important target for new therapeutics.

Compounds similar to the compounds of the present invention have previously been disclosed, cf. *J. Med. Chem.* **1999**, 42, 336, *J. Med. Chem.* **1992**, 35, 2369, DE 2804096, *J. Org. Chem.* **1996**, 61, 3849, *Bull. Soc. Chim. Fr.* **1969**, 319, WO 00/66578, WO 99/21845, and *J. Med. Chem.* **1968**, 11(6), 1144-1150. However, these references neither disclose nor suggest that these compounds may have a histamine H3 receptor antagonistic or agonistic activity.

Several publications disclose the preparation and use of histamine H3 agonists and antagonists. Most of these are imidazole derivatives. However, recently some imidazole-free ligands


of the histamine H3 receptor have been described (see e.g. Linney et al., *J. Med. Chem.* **2000**, *43*, 2362-2370; US 6,316,475, WO 01/66534 and WO 01/74810). However, these compounds differ structurally from the present compounds.

In view of the art's interest in histamine H3 receptor agonists, inverse agonists and antagonists, novel compounds which interact with the histamine H3 receptor would be a highly desirable contribution to the art. The present invention provides such a contribution to the art being based on the finding that a novel class of piperazines has a high and specific affinity to the histamine H3 receptor.

Due to their interaction with the histamine H3 receptor, the present compounds are useful in the treatment of a wide range of conditions and disorders in which an interaction with the histamine H3 receptor is beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

SUMMARY OF THE INVENTION

The invention relates to compounds according to formula I



[I]

wherein R¹ is selected from fluoro, bromo, iodo, hydroxy, trifluoromethoxy, C₂₋₆-alkoxy, C₁₋₆-alkyl, amino, C₂₋₆-alkylsulfanyl (-SH-C₂₋₆-alkyl), C₂₋₆-alkylsulfinyl (-SO-C₂₋₆-alkyl), C₂₋₆-alkylsulfonyl (-S(=O)₂-C₂₋₆-alkyl), C₁₋₆-alkylamino, di-C₁₋₆-alkylamino, cyano, nitro, aryl, heteroaryl and C₃₋₈-cycloalkyl; and pharmaceutically acceptable salts, solvates and prodrugs thereof.

The invention also relates to the use of said compounds in therapy, and in particular to pharmaceutical compositions comprising said compounds.

In another embodiment, the invention relates to methods of treatment, the method comprising administering to a subject in need thereof an effective amount of one or more compounds according to formula I.

In a still further embodiment, the invention relates to the use of compounds according to formula I in the manufacture of medicaments.

DEFINITIONS

In the structural formulae given herein and throughout the present specification, the following
5 terms have the indicated meaning:

The term "alkyl" as used herein represents a saturated, branched or straight hydrocarbon group having the indicated number of carbon atoms. Thus, the terms "C₁₋₃-alkyl", "C₁₋₆-alkyl" and "C₂₋₆-alkyl" as used herein represent saturated, branched or straight hydrocarbon groups having from 1 to 3 carbon atoms, 1 to 8 carbon atoms and 2 to 6 carbon atoms, respectively.

10 Typical alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl and the like.

The term "C₂₋₆-alkoxy" as used herein refers to the radical -O-C₂₋₆-alkyl, wherein C₂₋₆-alkyl is as defined above. Representative examples are ethoxy, n-propoxy, isopropoxy, butoxy, *sec*-
15 butoxy, *tert*-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.

The term "C₁₋₆-alkylamino" as used herein refers to the radical -NH-C₁₋₆-alkyl, wherein C₁₋₆-alkyl is as defined above. Representative examples are methylamino, ethylamino, isopropylamino, n-propylamino, butylamino, pentylamino, hexylamino and the like.

20

The term "di-C₁₋₆-alkylamino" as used herein refers to the radical -N(C₁₋₆-alkyl)₂, wherein C₁₋₆-alkyl is as defined above. It should be understood that the C₁₋₆-alkyl groups may be the same or different. Representative examples are dimethylamino, methylethylamino, diethylamino, diisopropylamino, di-n-propylamino, dibutylamino, dipentylamino, dihexylamino and the like.

25

The term "C₃₋₈-cycloalkyl" as used herein represents a monocyclic, carbocyclic group having from from 3 to 8 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl and the like.

30 The term "C₂₋₆-alkylsulfonyl" as used herein refers to the radical -S(=O)₂-C₂₋₆-alkyl, wherein C₂₋₆-alkyl is as defined above. Representative examples are ethylsulfonyl, isopropylsulfonyl, n-propylsulfonyl, butylsulfonyl, pentylsulfonyl and the like.

The term "aryl" as used herein is intended to include carbocyclic aromatic ring systems such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like.

The term "heteroaryl" as used herein is intended to include heterocyclic aromatic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazoliny, quinoliziny, quinoliny, isoquinoliny, quinoxaliny, naphthyridiny, pteridiny, carbazolyl, azepiny, diazepiny, acridiny and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, pyrroliny, pyrazoliny, indanyl, indoliny, oxazolidiny, oxazoliny, oxazepiny and the like.

20

The term "treatment" as used herein means the management and care of a patient for the purpose of combating a disease, disorder or condition. The term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition. The patient to be treated is preferably a mammal, in particular a human being.

25

The term "effective amount" as used herein is intended to indicate an amount of a compound (*in casu* a compound according to formula I) which when administered a patient gives rise to a therapeutically relevant response. Said amount may vary depending on e.g. the sex, age, in the weight and condition of the patient. It lies within the skills of an ordinary trained physician to determine what an effective amount in any particular treatment is.

30

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, R¹ represents bromo or cyano.

35

The compounds of the present invention interact with the histamine H3 receptor and are accordingly believed to be particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial.

5 In one aspect, the invention provides the use of a compound according to formula (I) in a pharmaceutical composition. The pharmaceutical composition may in another aspect of the invention comprise, as an active ingredient, at least one compound according to formula (I) together with one or more pharmaceutically acceptable carriers or excipients. In another aspect, the invention provides such a pharmaceutical composition in unit dosage form, comprising from about 0.05 mg to about 1000 mg, e.g. from about 0.1 mg to about 500 mg, such as from about 0.5 mg to about 200 mg of the compound according to formula (I).
10

In another aspect, the invention provides the use of a compound of formula (I) as defined above for the preparation of a pharmaceutical composition for the treatment of diseases and disorders in which an inhibition of the H3 histamine receptor has a beneficial effect.
15

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition having histamine H3 antagonistic activity or histamine H3 inverse agonistic activity.
20

In another aspect the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the reduction of weight.

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of overweight or obesity.
25

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the suppression of appetite or for satiety induction.

30 In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the prevention and/or treatment of disorders and diseases related to overweight or obesity, such as dyslipidaemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers.

35

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the prevention and/or treatment of eating disorders, such as bulimia or binge eating.

- 5 In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of IGT (Impaired glucose tolerance).

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of type 2 diabetes.

10

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to type 2 diabetes.

- 15 In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.

- 20 In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of diseases and disorders in which a stimulation of the H3 histamine receptor has a beneficial effect.

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition having histamine H3 agonistic activity.

25

In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of allergic rhinitis, ulcer or anorexia.

- 30 In another aspect, the invention provides the use of a compound of formula (I) for the preparation of a pharmaceutical composition for the treatment of Alzheimer's disease, narcolepsy, attention deficit disorders or reduced wakefulness, or for the regulation of sleep.

- 35 In another aspect, the invention relates to the use of a compound of formula (I) for the preparation of a pharmaceutical preparation for the treatment of airway disorders, such as asthma, for regulation of gastric acid secretion, or for treatment of diarrhoea.

In another aspect, the invention provides a method for the treatment of disorders or diseases related to the H3 histamine receptor, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula (I) as defined above, or of a pharmaceutical composition comprising such a compound.

In another aspect, the invention provides a method as described above, wherein the effective amount of the compound of the general formula (I) as defined above is in the range of from about 0.05 mg to about 2000 mg, preferably from about 0.1 mg to about 1000 mg, and more preferably from about 0.5 mg to about 500 mg per day.

In one aspect, the invention relates to compounds which exhibit histamine H3 receptor antagonistic activity or inverse agonistic activity and which may accordingly be useful in the treatment of a wide range of conditions and disorders in which histamine H3 receptor blockade is beneficial.

In another aspect, the invention provides a method for reduction of weight, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as defined above.

20

In another aspect, the invention provides a method for treatment of overweight or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

In another aspect, the invention provides a method for suppression of appetite or for satiety induction, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

In another aspect, the invention provides a method for prevention and/or treatment of disorders or diseases related to overweight or obesity, such as dyslipidaemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer, e.g. endometrial, breast, prostate or colon cancer, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

30

In another aspect, the invention provides a method for prevention and/or treatment of eating disorders, such as bulimia and binge eating, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

- 5 In another aspect, the invention provides a method for the treatment of IGT (Impaired glucose tolerance), the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

10 In another aspect, the invention provides a method for the treatment of type 2 diabetes, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

15 In another aspect, the invention provides a method for the delaying or prevention of the progression from IGT to type 2 diabetes, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

20 In another aspect, the invention provides a method for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

25 In another aspect, the invention relates to compounds which exhibit histamine H3 receptor agonistic activity and which may accordingly be useful in the treatment of a wide range of conditions and disorders in which histamine H3 receptor activation is beneficial.

30 Compounds of the present invention may also be used for the treatment of airway disorders (such as asthma), as anti-diarrhoeals, and for the modulation of gastric acid secretion. Furthermore, compounds of the present invention may be used for the treatment of diseases associated with the regulation of sleep and wakefulness, and for the treatment of narcolepsy and attention deficit disorders.

35 Moreover, compounds of the invention may be used as CNS stimulants or as sedatives. The present compounds may also be used for the treatment of conditions associated with epilepsy. Additionally, compounds of the invention may be used for the treatment of motion sickness and vertigo. Furthermore, they may be useful as regulators of hypothalamo-

hypophyseal secretion, as antidepressants, as modulators of cerebral circulation, and in the treatment of irritable bowel syndrome.

Further, compounds of the present invention may be used for the treatment of dementia and Alzheimer's disease.

5 Compounds of the present invention may also be useful for the treatment of allergic rhinitis, ulcer or anorexia.

Compounds of the present invention may furthermore be useful for the treatment of migraine [see, e.g., McLeod et al., *The Journal of Pharmacology and Experimental Therapeutics* **287** (1998), 43-50] and for the treatment of myocardial infarction [see Mackins et al., *Expert Opin-*
10 *ion on Investigational Drugs* **9** (2000), 2537-2542].

In a further aspect of the invention, treatment of a patient with a compound of the present invention is combined with diet and/or exercise.

In a further aspect of the invention, one or more compounds of the present invention is/are administered in combination with one or more further active substances in any suitable ra-
15 tio(s). Such further active agents may, for example, be selected from antiobesity agents, antidiabetics, antidyslipidemic agents, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes, and agents for the treatment of complications and disorders resulting from or associated with obesity.

Thus, in a further aspect of the invention one or more compounds of the present invention
20 may be administered in combination with one or more antiobesity agents or appetite regulat-
ing agents. Such agents may, for example, be selected from the group consisting of CART
(cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists,
MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF
(tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (cor-
25 ticotropin releasing factor binding protein) antagonists, urocortin agonists, β 3 adrenergic
agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH
(melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) an-
tagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors such as fluoxetine,
seroxat or citalopram, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and
30 noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antago-
nists, growth hormone, growth factors such as prolactin or placental lactogen, growth hor-
mone releasing compounds, TRH (thyrotropin releasing hormone) agonists, UCP 2 or 3
(uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin),
lipase/amylase inhibitors, PPAR (peroxisome proliferator-activated receptor) modulators,
35 RXR (retinoid X receptor) modulators, TR β agonists, AGRP (Agouti related protein) inhibi-

tors, opioid antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotrophic factor.

In one embodiment of the invention, an antiobesity agent administered in combination with one or more compounds of the invention is leptin.

5 In another embodiment, such an antiobesity agent is dexamphetamine or amphetamine.

In another embodiment, such an antiobesity agent is fenfluramine or dexfenfluramine.

In still another embodiment, such an antiobesity agent is sibutramine.

In a further embodiment, such an antiobesity agent is orlistat.

In another embodiment, such an antiobesity agent is mazindol or phentermine.

10 In still another embodiment, such an antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.

In yet a further aspect of the invention, one or more compounds of the present invention may be administered in combination with one or more antidiabetic agents. Relevant antidiabetic

15 290 (Novo Nordisk A/S), e.g. N^{B29}-tetradecanoyl des (B30) human insulin, EP 0 214 826 and

EP 0 705 275 (Novo Nordisk A/S), e.g. Asp^{B28} human insulin, US 5,504,188 (Eli Lilly), e.g.

Lys^{B28} Pro^{B29} human insulin, EP 0 368 187 (Aventis), e.g. Lantus®, all of which are incorporated herein by reference, GLP-1 derivatives, such as those disclosed in WO 98/08871

(Novo Nordisk A/S), incorporated herein by reference, as well as orally active hypoglycaemic

20 agents.

The orally active hypoglycaemic agents preferably comprise imidazolines, sulfonyleureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, α -glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the β -cells, e.g. potassium channel openers such as those disclosed in WO 97/26265,

25 WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by refer-

ence, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists, such as one of those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), both of which are incorporated herein by

reference, GLP-1 agonists, such as those disclosed in WO 00/42026 (Novo Nordisk A/S and

30 Agouron Pharmaceuticals, Inc.), incorporated herein by reference, DPP-IV (dipeptidyl pepti-

dase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antilipidemic agents, compounds lowering food intake, PPAR (perox-

isome proliferator-activated receptor) and RXR (retinoid X receptor) agonists, such as ALRT-268, LG-1268 or LG-1069.

In one embodiment of the invention, one or more compounds of the present invention may be administered in combination with insulin or an insulin analogue or derivative, such as
5 N^{B29}-tetradecanoyl des (B30) human insulin, Asp^{B28} human insulin, Lys^{B28} Pro^{B29} human insulin, Lantus®, or a mix-preparation comprising one or more of these.

In a further embodiment of the invention, one or more compounds of the present invention may be administered in combination with a sulfonylurea, e.g. tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.

10 In another embodiment of the invention, one or more compounds of the present invention may be administered in combination with a biguanide, e.g. metformin.

In yet another embodiment of the invention, one or more compounds of the present invention may be administered in combination with a meglitinide, e.g. repaglinide or nateglinide.

In still another embodiment of the invention, one or more compounds of the present invention
15 may be administered in combination with a thiazolidinedione insulin sensitizer, e.g. troglitazone, ciglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T 174, or a compound disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), all of which are incorporated herein by reference.

20 In still another embodiment of the invention, one or more compounds of the present invention may be administered in combination with an insulin sensitizer, e.g. such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516, or a compound disclosed in WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192 or WO 00/63193 (Dr. Reddy's Research
25 Foundation) or in WO 00/23425, WO 00/23415, WO 00/23451, WO 00/23445, WO 00/23417, WO 00/23416, WO 00/63153, WO 00/63196, WO 00/63209, WO 00/63190 or WO 00/63189 (Novo Nordisk A/S), all of which are incorporated herein by reference.

In a further embodiment of the invention, one or more compounds of the present invention may be administered in combination with an α -glucosidase inhibitor, e.g. voglibose, emigli-
30 tate, miglitol or acarbose.

In another embodiment of the invention, one or more compounds of the present invention may be administered in combination with an agent acting on the ATP-dependent potassium channel of the β -cells, e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.

In yet another embodiment of the invention, one or more compounds of the present invention may be administered in combination with nateglinide.

In still another embodiment, one or more compounds of the present invention may be administered in combination with an antihyperlipidemic agent or antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.

In still another embodiment of the invention, one or more compounds of the present invention may be administered in combination with an antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.

10 In another aspect of the invention, one or more compounds of the present invention may be administered in combination with more than one of the above-mentioned compounds, e.g. in combination with metformin and a sulfonylurea such as glyburide; a sulfonylurea and acarbose; nateglinide and metformin; acarbose and metformin; a sulfonylurea, metformin and troglitazone; insulin and a sulfonylurea; insulin and metformin; insulin, metformin and a sulfonylurea; insulin and troglitazone; insulin and lovastatin; etc.

15 Furthermore, one or more compounds of the present invention may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.

20 It should be understood that any suitable combination of compounds according to the invention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention.

30 Furthermore, some compounds of the present invention may exist in different tautomeric forms, and it is intended that any tautomeric forms which the compounds are able to form are included within the scope of the present invention.

The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of

suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pantoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.

Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.

The acid addition salts may be obtained as the direct products of compound synthesis. Alternatively, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. Compounds of the present invention may form solvates with standard low molecular weight solvents using methods well known to the person skilled in the art. Such solvates are also to be understood as being within the scope of the present invention.

The invention also encompasses prodrugs of the present compounds which following administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds which are readily convertible *in vivo* into the required compound of the formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The invention also encompasses active metabolites of the present compounds.

30 PHARMACEUTICAL COMPOSITIONS

The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accor-

dance with conventional techniques, such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route, such as the oral, rectal, nasal, pulmonary, topical (including buccal and sub-lingual), transdermal, intracisternal, intraperitoneal, vaginal or parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.

10 Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings, such as enteric coatings, or they can be formulated so as to provide controlled release of the active ingredient, such as sustained or prolonged release according to methods well known in the art.

15 Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also to be understood as being within the scope of the present invention.

Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferably from about 0.05 to about 10 mg/kg body weight per day, administered in one or more doses, such as from 1 to 3 doses. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated, and other factors evident to those skilled in the art.

The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day, such as from 1 to 3 times per day, may contain from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferably from about 0.5 mg to about 200

mg of a compound (or a salt or other derivative thereof as set forth above), according to the invention.

For parenteral routes, such as intravenous, intrathecal, intramuscular and similar administration, typical doses are of the order of about half the dose employed for oral administration.

5 The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is an acid addition salt of a compound having a free base functionality. When a compound of the formula (I) contains a free base functionality, such salts are prepared in a conventional manner by treating a solution or suspension
10 of the free base form of the compound of formula (I) with a chemical equivalent (acid-base equivalent) of a pharmaceutically acceptable acid. Representative examples of relevant inorganic and organic acids are mentioned above. Physiologically acceptable salts of a compound of the invention having an hydroxy group include the anion of said compound in combination with a suitable cation, such as sodium or ammonium ion.

For parenteral administration, solutions of the novel compounds of the formula (I) in sterile
15 aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to
20 those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylenes or water. Similarly, the carrier or diluent
25 may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the novel compounds of the formula (I) and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed
30 routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in

the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.

If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.

- 5 The amount of solid carrier may vary widely, but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid, such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet, which may be prepared by conventional tableting techniques, may contain:

10 Core:

Compound of the invention, e.g. compound of any of

Examples 1-8 (as free compound or salt thereof)	5.0 mg
---	--------

Lactosum Ph. Eur.	67.8 mg
-------------------	---------

Cellulose, microcryst. (Avicel)	31.4 mg
---------------------------------	---------

15 Amberlite® IRP88*	1.0 mg
----------------------	--------

Magnesii stearas Ph. Eur.	q.s.
---------------------------	------

Coating:

Hydroxypropyl methylcellulose	approx.	9 mg
-------------------------------	---------	------

20 Mywacett 9-40 T**	approx.	0.9 mg
----------------------	---------	--------

* Polacrillin potassium NF, tablet disintegrant, Rohm and Haas.

** Acylated monoglyceride used as plasticizer for film coating.

- 25 If desired, the pharmaceutical composition of the invention may comprise the compound of the formula (I) in combination with one or more further pharmacologically active substances, e.g. substances chosen among those described in the foregoing.

EXAMPLES

In the examples the following terms are intended to have the following, general meanings:

30 DIPEA: diisopropylethylamine

DMSO: dimethylsulphoxide

NMR

NMR spectra were recorded on Bruker 300 MHz and 400 MHz instruments.

LC-MS

HPLC-MS was performed on a Perkin Elmer instrument (API 100). The column used was X-Terra C18, 5 μ m, 50 X 3 mm, and elution was done at 1.5 ml/min at room temperature with a gradient of 5-90% acetonitrile in water with 0.01% trifluoroacetic acid over a period of 7.5 min.

5


HPLC

The RP-analyses was performed using an Alliance Waters 2695 system fitted with a Waters 2487 dual-band detector. UV detections were collected using a Symmetry C18 , 3.5 μ m, 3.0 mm x 100 mm column. The elution is done with a linear gradient consisting of 5-90% acetonitrile, 90-0% water and 5% of 1% aqueous trifluoroacetic acid over a period of 8 minutes at a flow-rate of 1.0 min/min.

10

General procedure (A)

Compounds of the general formula (I) may be prepared by the general procedure (A):



(Hal = halogen, notably Cl or Br)


A mixture of isopropylpiperazine (2.00 mmol), DMSO (1.0 ml), a suitable halopyridazine (2.00 mmol), and a base such as DIPEA (0.20 ml) is stirred for one hour at 100 °C and then for 18 hours at 120 °C. Water and potassium carbonate are added and the mixture is extracted with a solvent such as ethyl acetate (3 x 20 ml). The combined extracts are washed with brine, dried over magnesium sulphate, and concentrated under reduced pressure. The residue may be converted into an appropriate salt, such as the hydrochloride salt, by co-evaporation with an acid, such as 1 molar aqueous hydrochloric acid, ethanol and toluene, and the residue is then purified by recrystallization

20

25

General procedure (B)

Compounds of the general formula (I) may be prepared by the general procedure (B):




A compound of formula I may be prepared from a suitable monosubstituted piperazine and a suitable bromopyridazine in the presence of a suitable catalyst, such as, e. g., tris(dibenzylideneacetone)dipalladium, in a suitable solvent, such as toluene, at a suitable temperature between 0°C and 150°C.

5

General procedure (C)


Chloropyridazines of the general formula (IIa), (IIb) or (IIc) may be prepared by the general procedure (C):



10

Example 1

4-[6-(4-Isopropylpiperazin-1-yl)-pyridazin-3-yl]benzonitrile




A suspension of 4-(6-chloro-pyridazin-3-yl)-benzotrile (1 g, 4.64 mmol; prepared as described in US patent No. 4,112,095), isopropylpiperazine (0.654 g, 5.1 mmol), DIPEA (1.199 g, 9.27 mmol) and 4-(dimethylamino)pyridine (0.057g, 0.464 mmol) in DMSO (4 ml) was stirred and heated to 100 °C for 20h. After cooling to room temperature, the mixture was diluted with dichloromethane (25 ml) and water (35 ml) and stirred for 5 min. The organic phase was separated, washed with water (50 ml) and brine (50 ml), and acidified to pH 2 by addition of 1N hydrochloric acid. The mixture was extracted with water (30 ml), and the aqueous phase was washed with dichloromethane (10 ml) and concentrated in vacuo to give a solid, which was collected and stripped with ethanol to afford the title compound as a crystalline hydrochloride (1.33 g, 76%).

$^1\text{H NMR}$ (D_2O) δ 1.30 (d, 6H), 3.26 (broad t, 2H), 3.45-3.68 (m, 5H), 4.52 (broad d, 2H), 7.75 (d, 1H), 7.77 (d, 2H), 7.87 (d, 2H), 8.12 (d, 1H);

HPLC-MS: m/z 308.2 (MH^+); R_t : 1.76 min.

15 Example 2

3-(4-Bromophenyl)-6-(4-isopropylpiperazin-1-yl)pyridazine




This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-chloro-6-(4-bromophenyl)pyridazine, prepared as described in US patent No. 4,112,095. The compound was isolated as its hydrochloride salt.

$^1\text{H NMR}$ (D_2O): δ 1.30 (d, 6H), 3.23 (broad t, 2H), 3.47 (broad t, 2H), 3.52-3.67 (m, 3H), 4.52 (broad d, 2H), 7.64 (d, 2H), 7.67 (d, 2H), 7.82 (d, 1H), 8.15 (d, 1H);

HPLC: R_t = 3.49 min.

25 Example 3

3-(4-Ethanesulfonylphenyl)-6-(4-isopropylpiperazin-1-yl)pyridazine




This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-chloro-6-(4-ethanesulfonylphenyl)pyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.

^1H NMR (d_6 -DMSO): δ 1.15 (t, 3H), 1.33 (d, 6H), 3.17 (m, 2H), 3.36 (q, 2H), 3.45-3.60 (m, 3H), 3.67 (t, 2H), 4.66 (d, 2H), 7.71 (d, 1H), 8.00 (d, 2H), 8.29 (d, 1H), 8.33 (d, 2H);

HPLC: R_t = 4.73 min.

5 Example 4

3-(4-Ethanesulfinylphenyl)-6-(4-isopropylpiperazin-1-yl)pyridazine



This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-chloro-6-(4-ethanesulfinylphenyl)pyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.


^1H NMR (d_6 -DMSO): δ 1.06 (t, 3H), 1.32 (d, 6H), 2.83 (m, 1H), 3.05-3.24 (m, 3H), 3.46-3.59 (m, 3H), 3.68 (broad t, 2H), 4.64 (broad d, 2H), 7.75-7.83 (m, 3H), 8.26 (d, 2H), 8.32 (d, 1H), 11.47 (broad s, 1H);

HPLC: R_t = 4.10 min.

15

Example 5

3-[4-(Butane-1-sulfonyl)phenyl]-6-(4-isopropylpiperazin-1-yl)pyridazine




This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-[4-(butane-1-sulfonyl)phenyl]-6-chloropyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.

^1H NMR (d_6 -DMSO): δ 0.84 (t, 3H), 1.33 (d, 6H), 1.3-1.4 (m, 2H), 1.54 (m, 2H), 3.17 (m, 2H), 3.37 (m, 2H), 3.45-3.60 (m, 3H), 3.67 (broad t, 2H), 4.66 (broad d, 2H), 7.73 (d, 1H), 8.03 (d, 2H), 8.30 (d, 1H), 8.34 (d, 2H), 11.41 (broad s, 1H);

25 HPLC: R_t = 6.46 min.

Example 6

3-[4-(Butane-1-sulfinyl)phenyl]-6-(4-isopropylpiperazin-1-yl)pyridazine



This compound was prepared according to General Procedure (A), starting from 1-


- 5 isopropylpiperazine and 3-[4-(butane-1-sulfinyl)phenyl]-6-chloropyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.

$^1\text{H NMR}$ (d_6 -DMSO): δ 0.87 (t, 3H), 1.26-1.50 (m, 9H), 1.65 (m, 1H), 2.83 (m, 1H), 3.02 (m, 1H), 3.18 (m, 2H), 3.45-3.60 (m, 3H), 3.68 (broad t, 2H), 4.64 (broad d, 2H), 7.74-7.86 (m, 3H), 8.26 (d, 2H), 8.32 (d, 1H), 11.41 (broad s, 1H);

- 10 HPLC: $R_t = 5.52$ min.

Example 7

3-(4-Isopropylpiperazin-1-yl)-6-[4-(propane-1-sulfonyl)phenyl]pyridazine




- 15 This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-chloro-6-[4-(propane-1-sulfonyl)phenyl]pyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.

$^1\text{H NMR}$ (d_6 -DMSO): δ 0.94 (t, 3H), 1.33 (d, 6H), 1.59 (m, 2H), 3.17 (m, 2H), 3.35 (m, 2H), 3.45-3.60 (m, 3H), 3.68 (broad t, 2H), 4.67 (broad d, 2H), 7.74 (d, 1H), 8.02 (d, 2H), 8.81 (d, 20 1H), 8.84 (d, 2H), 11.44 (broad s, 1H);

HPLC: $R_t = 5.60$ min.

Example 8

3-(4-Isopropylpiperazin-1-yl)-6-[4-(propane-1-sulfinyl)phenyl]pyridazine



This compound was prepared according to General Procedure (A), starting from 1-isopropylpiperazine and 3-chloro-6-[4-(propane-1-sulfinyl)phenyl]pyridazine, prepared according to General Procedure (C). The compound was isolated as its hydrochloride salt.

¹H NMR (d₆-DMSO): δ 0.98 (t, 3H), 1.33 (d, 6H), 1.50 (m, 1H), 1.70 (m, 1H), 2.82 (m, 1H),
5 2.99 (m, 1H), 3.18 (m, 2H), 3.45-3.60 (m, 3H), 3.69 (broad t, 2H), 4.65 (broad d, 2H), 7.75-
7.85 (m, 3H), 8.26 (d, 2H), 8.32 (d, 1H), 11.47 (broad s, 1H);
HPLC: R_t = 4.76 min.

PHARMACOLOGICAL METHODS

The ability of the compounds to interact with the histamine H3 receptor can be determined by
10 the following *in vitro* binding assays.

Binding assay I

Rat cerebral cortex is homogenized in ice cold K-Hepes, 5 mM MgCl₂ pH 7.1 buffer. After two differential centrifugations the last pellet is resuspended in fresh Hepes buffer containing 1 mg/ml bacitracin. Aliquots of the membrane suspension (400 μ g/ml) are incubated for 60 min
15 at 25°C with 30 pM [¹²⁵I]-iodoproxifan (a known histamine H3 receptor antagonist) and the test compound at various concentrations. The incubation is stopped by dilution with ice-cold medium, followed by rapid filtration through Whatman GF/B filters pretreated for 1 hour with 0.5% polyethyleneimine. The radioactivity retained on the filters is counted using a Cobra II auto gamma counter. The radioactivity of the filters is indirectly proportional to the binding
20 affinity of the tested compound. The results are analyzed by non-linear regression analysis.

Binding assay II

The H3-receptor agonist ligand R- α -methyl[³H]histamine (RAMHA) is incubated with isolated rat cortex cell-membranes at 25 °C for 1 hour, followed by a filtration of the incubate through Whatman GF/B filters. Radioactivity retained on the filters is measured using a beta counter.
25 Male Wistar rats (150-200 g) are decapitated, and cerebral cortex is quickly dissected out and frozen immediately on dry ice. Tissue is kept at -80 °C until membrane preparation. During the membrane preparation the tissue is kept on ice all the time. Rat cerebral cortex is homogenized in 10 volumes (w/w) ice-cold Hepes buffer (20 mM Hepes, 5 mM MgCl₂ pH 7.1 (KOH) + 1 mg/ml bacitracin) using an Ultra-Turrax homogenizer for 30 seconds. The ho-
30 mogenate is centrifuged at 140 g in 10 min. The supernatant is transferred to a new test tube and centrifuged for 30 min at 23 000 g. Pellet is resuspended in 5-10 ml Hepes buffer, homogenized and centrifuged for 10 min at 23 000 g. This short centrifugation step is repeated

twice. After the last centrifugation the pellet is resuspended in 2-4 ml Hepes buffer and the protein concentration is determined. The membranes are diluted to a protein concentration of 5 mg/ml using Hepes buffer, aliquoted and stored at -80°C until use.

50 μl test-compound, 100 μl membrane (200 $\mu\text{g}/\text{ml}$), 300 μl Hepes buffer and 50 μl R- α -methyl[^3H]histamine (1 nM) are mixed in a test tube. The compounds to be tested are dissolved in DMSO and further diluted in H_2O to the desired concentrations. Radioligand and membranes are diluted in Hepes buffer + 1 mg/ml bacitracin. The mixture is incubated for 60 min at 25°C . Incubation is terminated by addition of 5 ml ice-cold 0.9% NaCl, followed by rapid filtration through Whatman GF/B filters pre-treated for 1 hour with 0.5% polyethyleneimine. The filters are washed with 2 x 5 ml ice-cold NaCl. To each filter is added a 3 ml scintillation cocktail, and the retained radioactivity is measured with a Packard Tri-Carb beta counter.

IC_{50} values are calculated by non-linear regression analysis of binding curves (6 points minimum) using the windows program GraphPad Prism, GraphPad software, USA.

15 **Binding assay III**

The human H3 receptor is cloned by PCR and subcloned into the pcDNA3 expression vector. Cells stably expressing the H3 receptor are generated by transfecting the H3-expression vectors into HEK 293 cells and using G418 to select for H3 clones. The human H3-HEK 293 clones are cultured in DMEM (GIBCO-BRL) with glutamax, 10% foetal calf serum, 1% penicillin/streptavidin and 1 mg/ml G 418 at 37°C and 5% CO_2 . Before harvesting, the confluent cells are rinsed with PBS and incubated with Versene (proteinase, GIBCO-BRL) for approximately 5 min. The cells are flushed with PBS and DMEM and the cell suspension collected in a tube and centrifuged for 5-10 min at 1500 rpm in a Heraeus Sepatech Megafuge 1.0. The pellet is resuspended in 10-20 vol. Hepes buffer [20 mM Hepes, 5 mM MgCl_2 , pH 7.1 (KOH)] and homogenized for 10-20 seconds using an Ultra-Turrax homogenizer. The homogenate is centrifuged for 30 min at 23 000 g. The pellet is resuspended in 5-10 ml Hepes buffer, homogenized 5-10 seconds with the Ultra-Turrax and centrifuged for 10 min at 23 000 g. Following this centrifugation step, the membrane pellet is resuspended in 2-4 ml Hepes buffer, homogenized with a syringe or Teflon homogenizer, and the protein concentration determined. The membranes are diluted to a protein concentration of 1-5 mg/ml in Hepes buffer, aliquoted and kept at -80°C until use.

Aliquots of the membrane suspension are incubated for 60 min at 25°C with 30 pM [^{125}I]-iodoproxifan (a known compound with high affinity for the H3 receptor) and the test compound at various concentrations. The incubation is stopped by dilution with ice-cold medium,

followed by rapid filtration through Whatman GF/B filters pretreated for 1 hour with 0.5% polyethyleneimine. The radioactivity retained on the filters is counted using a Cobra II auto gamma counter. The radioactivity of the filters is indirectly proportional to the binding affinity of the tested compound. The results are analysed by non-linear regression analysis.

5 When tested, the present compounds of the formula (I) generally show a high binding affinity to the histamine H3 receptor.

Preferably, the compounds according to the invention have an IC₅₀ value as determined by one or more of the assays of less than 10 μM, more preferably less than 1 μM, and still more preferably less than 500 nM, such as less than 100 nM.

10 **Functional assay I**

The ability of the compounds to interact with the histamine H3 receptor as agonists, inverse agonists and/or antagonists, is determined by an *in vitro* functional assay utilizing membranes from HEK 293 cell expressing the human H3 receptors.

15 The H3 receptor is cloned by PCR and subcloned into the pcDNA3 expression vector. Cells stably expressing the H3 receptor are generated by transfecting the H3-expression vectors into HEK 293 cells and using G418 to select for H3 clones. The human H3-HEK 293 clones are cultured in DMEM with glutamax, 10% foetal calf serum, 1% penicillin/streptavidin and 1 mg/ml G 418 at 37°C and 5% CO₂.

20 The H3 receptor expressing cells are washed once with phosphate buffered saline (PBS) and harvested using versene (GIBCO-BRL). PBS is added and the cells are centrifuged for 5 min at 188 g. The cell pellet is resuspended in stimulation buffer to a concentration of 1 x 10⁶ cells/ml. cAMP accumulation is measured using the Flash Plate® cAMP assay (NEN™ Life Science Products). The assay is generally performed as described by the manufacturer.

25 Briefly, 50 μl cell suspension is added to each well of the Flashplate which also contained 25 μl 40 μM isoprenaline, to stimulate cAMP generation, and 25 μl of test compound (either agonists or inverse agonists alone, or agonist and antagonist in combination). The assay can be run in "agonist-mode" in which the test compound is added, in increasing concentration, on its own, to the cells, and cAMP is measured. If cAMP goes up, the compound in question is an inverse agonist; if cAMP does not change, it is a neutral antagonist, and if cAMP goes
30 down, it is an agonist. The assay can also be run in the "antagonist-mode" in which a test compound is added, in increasing concentrations, together with increasing concentrations of a known H3 agonist (e.g. RAMHA). If the test compound is an antagonist, increasing concentrations of it cause a right-ward shift in the H3-agonist's dose-response curves. The final volume in each well is 100 μl. Test compounds are dissolved in DMSO and diluted in H₂O. The

mixture is shaken for 5 min, and allowed to stand for 25 min at room temperature. The reaction is stopped with 100 μ l "Detection Mix" per well. The plates are then sealed with plastic, shaken for 30 min, allowed to stand overnight, and finally the radioactivity is counted in the Cobra II auto gamma topcounter. EC₅₀ values are calculated by non-linear regression analysis of dose response curves (6 points minimum) using GraphPad Prism. Kb values are calculated by Schild plot analysis.

Functional assay II

The ability of the compounds to bind and interact with the human H3 receptor as agonists, inverse agonists and/or antagonists, is determined by a functional assay, named [³⁵S] GTP γ S assay. The assay measures the activation of G proteins by catalyzing the exchange of guanosine 5'-diphosphate (GDP) by guanosine 5'-triphosphate (GTP) at the α -subunit. The GTP-bounded G proteins dissociate into two subunits, G α _{GTP} and G $\beta\gamma$, which in turn regulate intracellular enzymes and ion channels. GTP is rapidly hydrolysed by the G α -subunit (GTPases) and the G protein is deactivated and ready for a new GTP exchange cycle.

To study the function of ligand-induced G protein coupled receptor (GPCR) activation by an increase in guanine nucleotide exchange at the G proteins, the binding of [³⁵S]-guanosine-5'-O-(3-thio) triphosphate [³⁵S] GTP γ S, a non-hydrolysed analogue of GTP, is determined. This process can be monitored *in vitro* by incubating cell membranes containing the G protein coupled receptor H3 with GDP and [³⁵S] GTP γ S. Cell membranes are obtained from CHO cells stably expressing the human H3 receptor. The cells are washed twice in PBS, harvested with PBS+1 mM EDTA, pH 7.4 and centrifuged at 1000 rpm for 5 min. The cell pellet is homogenized in 10 ml ice-cold Hepes buffer (20 mM Hepes, 10 mM EDTA pH 7.4 (NaOH)) using an Ultra-Turrax homogenizer for 30 seconds and centrifuged for 15 min at 20.000 rpm. Following this centrifugation step, the membrane pellet is resuspended in 10 ml ice-cold Hepes buffer (20 mM Hepes, 0.1 mM EDTA pH 7.4 (NaOH)) and homogenized as described above. This procedure is repeated twice except for the last homogenization step, the protein concentration is determined, and membranes are diluted to a protein concentration of 2 mg/ml, aliquoted and kept at -80 °C until use.

In order to study the presence and the potency of an inverse agonist/antagonist, the H3-receptor agonist ligand R- α -methyl histamine (RAMHA) is added. The ability of the test compound to counteract the effect of RAMHA is measured. When studying the effect of an agonist, RAMHA is not added to the assay medium. The test compound is diluted in the assay buffer (20 mM HEPES, 120 mM NaCl, 10 mM MgCl₂ pH 7.4 (NaOH)) at various concentrations followed by addition of 10⁻⁸ nM RAMHA (only in the case where an inverse ago-

nist/antagonist is examined), 3 μM GDP, 2.5 μg membranes, 0.5 mg SPA beads and 0.1 nM [^{35}S] GTP γS , and incubation for 2 hours with gentle shaking at room temperature. The plates are centrifuged at 1500 rpm for 10 min and the radioactivity is measured using a Top-counter. The results are analyzed by non-linear regression and the IC_{50} value is determined.

5 RAMHA and other H3 agonists stimulate the binding of [^{35}S] GTP γS to membranes expressing the H3 receptor. In the antagonist/inverse agonist test, the ability of increasing amounts of test compound to inhibit the increased [^{35}S] GTP γS binding by 10^{-8} M RAMHA is measured as a decrease in radioactivity signal. The IC_{50} value determined for an antagonist is the ability of this compound to inhibit the effect of 10^{-8} M RAMHA by 50%. In the agonist test, the ability

10 of increasing amounts of test compound is measured as an increase in radioactivity signal. The EC_{50} value determined for an agonist is the ability of this compound to increase the signal by 50% of the maximal signal that is obtained by 10^{-5} M RAMHA. Preferably, the antagonists and agonists according to the invention have an $\text{IC}_{50}/\text{EC}_{50}$ value (as determined by one or more of the assays described above) of less than 10 μM , more

15 preferably less than 1 μM , and still more preferably less than 500 nM, such as less than 100 nM.

The open cage Schedule-fed rat model

The ability of the present compounds to reduce weight is determined using the *in vivo* open cage Schedule-fed rat model.

20 Sprague-Dawley (SD) male rats of an age of about 1½ to 2 months and a weight of about 200-250 g are purchased from Møllegaard Breeding and Research Centre A/S (Denmark). On arrival they are allowed some days of acclimatisation before being placed in individual open plastic cages. They are habituated to the presence of food (Altromin pelleted rat chow) in their home cage for only 7 hours each day (from 07.30 to 14.30, seven days a week). Water

25 is present ad libitum. Once the consumption of food has stabilised after 7 to 9 days, the animals are ready for use.


Each animal is used only once to avoid carry-over effects between treatments. During the test sessions, the test compound is administered intraperitoneally or orally 30 min before the start of the sessions. One group of animals is administered the test compound at different

30 doses, and a control group of animals receives vehicle. Food and water intake are monitored at 1, 2 and 3 hours post administration.

Any side effects (manifested as barrel-rolling, bushy fur etc.) may rapidly be detected, since the animals are kept in transparent plastic cages to enable continuous monitoring.

CLAIMS

1. A compound according to formula I



5

[I]

wherein R¹ is independently selected from fluoro, bromo, iodo, hydroxy, trifluoromethoxy, C₂₋₆-alkoxy, C₁₋₆-alkyl, amino, C₂₋₆-alkylsulfanyl, C₂₋₆-alkylsulfinyl, C₂₋₆-alkylsulfonyl, C₁₋₆-alkylamino, di-C₁₋₆-alkylamino, cyano, nitro, aryl, heteroaryl and C₃₋₈-cycloalkyl; and pharmaceutically acceptable salts, solvates and prodrugs thereof.

10

2. A compound according to claim 1, wherein R¹ represents bromo or cyano.

3. A compound according to claim 1 or 2 for use in therapy.

15

4. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 or 2 together with one or more pharmaceutically acceptable carriers or excipients.

5. A pharmaceutical composition according to claim 4 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg, more preferably from about 0.5 mg to about 200 mg of a compound according to claim 1 or 2.

20

6. Use of a compound according to claim 1 or 2 for the preparation of a pharmaceutical composition for the treatment of disorders and diseases related to the histamine H₃ receptor.

25

7. The use according to claim 6 for the preparation of a pharmaceutical composition for the reduction of weight.

8. The use according to claim 6 for the preparation of a pharmaceutical composition for the treatment of overweight or obesity.

30

9. The use according to claim 6 for the preparation of a pharmaceutical composition for the suppression of appetite or for satiety induction.
10. The use according to claim 6 for the preparation of a pharmaceutical composition for the prevention and/or treatment of disorders and diseases related to overweight or obesity.
11. The use according to claim 6 for the preparation of a pharmaceutical composition for the prevention and/or treatment of eating disorders, such as bulimia or binge eating.
12. The use according to claim 6 for the preparation of a pharmaceutical composition for the treatment of IGT.
13. The use according to claim 6 for the preparation of a pharmaceutical composition for the treatment of type 2 diabetes.
14. The use according to claim 6 for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to type 2 diabetes.
15. The use according to claim 6 for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.
16. The use according to claim 6 for the preparation of a pharmaceutical composition for the treatment of allergic rhinitis, ulcer or anorexia.
17. The use according to claim 6 for the preparation of a pharmaceutical composition for the treatment of Alzheimer's disease, narcolepsy or attention deficit disorders.
18. A method for the treatment of disorders or diseases related to the H3 histamine receptor, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or 2.
19. A method according to claim 18, wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg, preferably from about 0.1 mg to about 1000 mg, more preferably from about 0.5 mg to about 500 mg per day.

20. A method according to claim 18 or 19 for the reduction of weight.
21. A method according to claim 18 or 19 for the treatment of overweight or obesity.
- 5 22. A method according to claim 18 or 19 for the suppression of appetite or for satiety induction.
23. A method according to claim 18 or 19 for the prevention and/or treatment of disorders and diseases related to overweight or obesity.
- 10 24. A method according to claim 18 or 19 for the prevention and/or treatment of eating disorders, such as bulimia or binge eating.
- 15 25. A method according to claim 18 or 19 for the treatment of IGT.
26. A method according to claim 18 or 19 for the treatment of type 2 diabetes.
27. A method according to claim 18 or 19 for the delaying or prevention of the progression from IGT to type 2 diabetes.
- 20 28. A method according to claim 18 or 19 for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.
- 25 29. A method according to claim 18 or 19 for the treatment of allergic rhinitis, ulcer or anorexia.
30. A method according to claim 18 or 19 for the treatment of Alzheimer's disease, narcolepsy or attention deficit disorders.

INTERNATIONAL SEARCH REPORT

International Application No

P/DK2004/000483

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D237/20 A61K31/501 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WALCZYNSKI K ET AL: "Non-imidazole histamine H3 ligands, part 2: new 2-substituted benzothiazoles as histamine H3 antagonists" ARCHIV DER PHARMAZIE, vol. 332, no. 11, 1999, pages 389-398, XP001097557 the whole document	1,6,18
P,X	WO 03/066604 A (NOVO NORDISK A/S ET AL) 14 August 2003 (2003-08-14) the whole document, particularly examples 59, 62, 63, 70 and 72	1-30



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 September 2004

Date of mailing of the international search report

28/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK2004/000483

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 18-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK2004/000483

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03066604	A	14-08-2003	WO 03066604 A2	14-08-2003
			US 2003236259 A1	25-12-2003
